BioXCell--RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)
產(chǎn)品描述：
10F.9G2™-CP001單克隆抗體是原始10F.9G2™單克隆抗體的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始10F.9G2™克隆號(hào)相同，但是恒定區(qū)序列已經(jīng)從大鼠IgG2b變?yōu)樾∈驣gG1。10F.9G2™-CP001單克隆抗體在Fc片段中也含有D265A突變，使其無法與內(nèi)源性Fcγ受體結(jié)合。
10F.9G2™-CP001單克隆抗體與小鼠PD-L1（程序性死亡配體1，也稱為B7-H1或CD274）反應(yīng)。PD-L1是屬于Ig超家族的B7家族的I型跨膜蛋白，分子量為40kDa。PD-L1在T淋巴細(xì)胞、B淋巴細(xì)胞、NK細(xì)胞、樹突狀細(xì)胞以及IFNγ刺激的單核細(xì)胞、上皮細(xì)胞和內(nèi)皮細(xì)胞上表達(dá)。PD-L1與CD4和CD8胸腺細(xì)胞以及活化的T和B淋巴細(xì)胞和骨髓細(xì)胞上的受體PD-1結(jié)合。PD-L1與PD-1的結(jié)合導(dǎo)致抑制TCR介導(dǎo)的T細(xì)胞增殖和細(xì)胞因子產(chǎn)生。PD-L1被認(rèn)為在腫瘤免疫逃逸中起著重要作用。誘導(dǎo)的PD-L1表達(dá)在許多腫瘤中很常見，并導(dǎo)致腫瘤細(xì)胞對(duì)CD8+ T細(xì)胞介導(dǎo)的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通過用阻斷PD-L1和PD-1之間相互作用的抗體進(jìn)行治療，暫時(shí)抑制腫瘤生長(zhǎng)。10F.9G2™單克隆抗體已被證明可以阻斷PD-L1和PD-1之間以及PD-L1和B7-1之間的相互作用（CD80）。
產(chǎn)品詳情：
|
產(chǎn)品名稱 |
RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) |
|
產(chǎn)品貨號(hào) |
CP001 |
|
產(chǎn)品規(guī)格 |
1mg |
|
反應(yīng)種屬 |
Mouse |
|
克隆號(hào) |
10F.9G2™-CP001 |
|
同種型 |
Mouse IgG1(switched from rat IgG2b) |
|
免疫原 |
Mouse CD274 |
|
實(shí)驗(yàn)應(yīng)用 |
in vivo PD-L1 blockade* Immunofluorescence* Immunohistochemistry (frozen)* Flow cytometry* Western blot* *Reported for the original rat IgG2b 10F.9G2 antibody |
|
產(chǎn)品形式 |
PBS, pH 7.0,Contains no stabilizers or preservatives |
|
純度 |
>95%, Determined by SDS-PAGE |
|
聚合 |
<5%, Determined by SEC |
|
無菌處理 |
0.2 µm filtration |
|
純化方式 |
Protein A |
|
分子量 |
150 kDa |
|
小鼠病原檢測(cè) |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
|
保存條件 |
抗體原液保存在4°C，不能冷凍保存。 |
|
推薦抗體稀釋液 |
InVivoPure pH 7.0 Dilution Buffer（貨號(hào)IP0070） |
該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：
|
應(yīng)用 |
文章 |
|
體內(nèi)PD-L1阻斷 (in vivo PD-L1 blockade) |
1. Grasselly, C., et al. (2018). 'The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent' Front Immunol 9: 2100.
2. Stathopoulou, C., et al. (2018). 'PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells' Immunity 49(2): 247-263 e247.
3. Jaworska, K., et al. (2015). 'Both PD-1 ligands protect the kidney from ischemia reperfusion injury' J Immunol 194(1): 325-333.
4. Kim, J., et al. (2015). 'Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help' Nat Commun 6: 7994.
5. Zander, R. A., et al. (2015). 'PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity' Cell Host Microbe 17(5): 628-641. |
|
體內(nèi)PD-L1阻斷，流式細(xì)胞術(shù) (in vivo PD-L1 blockade, Flow Cytometry) |
1. Aloulou, M., et al. (2016). 'Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells' Nat Commun 7: 10579.
2. Ngiow, S. F., et al. (2015). 'A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1' Cancer Res 75(18): 3800-3811.
3. Rutigliano, J. A., et al. (2014). 'Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells' J Virol 88(3): 1636-1651. |
|
體內(nèi)PD-L1阻斷，免疫熒光 (in vivo PD-L1 blockade, Immunofluorescence) |
1.Willimsky, G., et al. (2013). 'Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance' J Clin Invest 123(3): 1032-1043. |
|
免疫組織化學(xué)（冷凍），免疫熒光 (Immunohistochemistry (frozen), Immunofluorescence) |
1.Riella, L. V., et al. (2011). 'Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts' Am J Transplant 11(4): 832-840. |
更多產(chǎn)品詳情請(qǐng)咨詢 BioXCell 中國授權(quán)代理——欣博盛生物
全國服務(wù)熱線: 4006-800-892 郵箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029
廣州：020-87615159 上海: 021-34613729
代理品牌網(wǎng)站: www.neobioscience.com
自主品牌網(wǎng)站: www.neobioscience.net